An evolving VTE management environment: daily practices and new challenges
Chairmen: Sylvia Haas, Germany; Joseph Caprini, USA 
| 6:30 | Welcome and Introduction Sylvia Haas, Germany |
| Building on experience | |
| 6:35 | What experience tells us: Clinical cases Bernardo Menajovski, USA |
| Experience applied to special populations | |
| 7:00 | Renal insufficiency Sylvia Haas, Germany |
| 7:20 | Cancer patients Alok Khorana, USA |
| What the future holds | |
| 7:40 | Oral anticoagulants: do we know all on their benefit and safety? Joseph Caprini, USA |
| 8:00 | Biosimilars LMWH ISTH/SSC recommendations: an update Job Harenberg, Germany |
| 8:20 | Closing remarks Joseph Caprini, USA |
Future Directions in VWD, Hemophilia and other Bleeding Disorders 
Chairmen: Wing-Yen Wong, Baxter, USA and David Lillicrap, Canada
| 18:30 | Introduction Chair |
| 18:35 |
An evolving treatment paradigm for VWD Unmet needs in von Willebrand Disease Insights from the biochemical and structural characterization of rVWF Update on Baxter’s rVWF clinical program - |
| 19:40 |
Novel pharmaceutical approaches to improving hemostasis TFPI inhibition and non-anticoagulant sulphated polysaccharides (NASP) |
| 20:00 | Advances in the understanding of ADAMTS13 Fritz Scheiflinger,Baxter, Austria |
| 20:20 | Q&A and Conclusion Chair |
The Role of LMWHs beyond anticoagulation
Chairman: Prof. Ahmed Saad Eldin, Egypt
| 12:45 | Chairman’s introduction |
| 12:50 | Long term treatment of DVT with LMWH in post thrombotic syndrome Christos Liapis, Greece |
| 13:20 | Key role of LMWH in inflammation and cancer Shaker Mousa, USA |
| 13:50 | Discussion |
| 14:10 | Chairman’s closing remarks |
| 14:15 | End of symposium |
VTE Recurrence ... why accept this?
Chairmen: Professor Martin Prins, Netherlands 
|
13:00 |
Welcome and Introduction |
|
13:05 |
VTE Recurrence ... why accept this? |
|
13:30 |
Questions and Answers |
Recombinant therapy for the management of haemophilia: experience from clinical practice
Chairman: Dr Magdy El Ekiaby, Egypt
Co-chairman: Prof. Brian Colvin, UK
| 12:45 | Chairman’s Welcome Magdy El Ekiaby, Egypt |
| 12:50 | Delivering Optimal Therapy for Haemophilia B: Recombinant FIX – Clinical Evidence and Experience Paul Giangrande, UK |
| 13:20 | Questions and Answers |
| 13:30 | Moroctocog alfa – Clinical Evidence and Experience Alfonso Iorio, Italy |
| 14:00 | Questions and Answers |
| 14:10 | Summary and Close |
From disease to diagnostics
Chairmen: Magdy El Ekiaby, Egypt; Aida Inbal, Israel
Chairman/Moderator: Johannes Oldenburg, Germany
| 13.15 |
Welcome and introduction from the Chairs |
| 13.25 | Rare bleeding disorders and aspects of FXIII deficiency Flora Peyvandi, Italy |
| 13.45 | Production and characterisation of recombinant FXIII Lene Hørlyck, Novo Nordisk, Denmark |
| 14.00 | State-of-the-art production of a new recombinant FVIII (N8) Knud Vad, Novo Nordisk, Denmark |
| 14.15 | Novo Nordisk recombinant FVIII – pharmacokinetic study data Uriel Martinowitz, Israel |
| 14.35 | Questions and answers, and concluding remarks Chairmen |
| 14.45 | Symposium close |
Tuesday May 25, 2010
Standardization of Thrombin Generation and first clinical applications
Chairman: Claude Negrier, France
| 07:30 | Welcome and Introduction Claude Negrier , France |
| 07:35 | Pre-analytical and analytical standardization of Thrombin Generation towards clinical applications Hugo Ten Cate, The Netherlands |
| 07:55 | Management of bleeding disorders using Thrombin Generation Claude Negrier, France< |
| 08:15 | Questions and Answers Claude Negrier, France Hugo Ten Cate, The Netherlands |